EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Heterologous mucosal vaccine boosting enhances mucosal and systemic immunity by distinct mechanisms

Cameron Bissett, Lyn Yong, Alexandra J. Spencer, Fionn Nok Lam Ma, Ethan A. Courchesne, Reshma Koolaparambil Mukesh, Marta Ulaszewska, Alexander Sampson, Marie Lucienne, Reshma Kailath, Susan Morris, Claire Powers, Sandra Belij-Rammerstorfer, Vincent J. Munster, Neeltje van Doremalen, Nicholas M. Provine, Teresa Lambe

Journal of Experimental Medicine · 2026-01-05 · 223 (1)

DOI: 10.1084/jem.20241529 ↗
AbstractBibliografische Angaben

Abstract

Seasonal booster vaccination is the primary intervention for protection from respiratory viral infections, such as influenza virus or SARS-CoV-2. However, efficacy is often limited because immune exposure to prior strains impairs development of new responses. In this study, we sought to determine how this issue could be overcome in a mouse model of heterologous immunization against WT and omicron strains of SARS-CoV-2. Intranasal booster immunization circumvented the shortcomings of intramuscular immunization, resulting in superior systemic and mucosal T and B cell immunity and better viral control following SARS-CoV-2 challenge in hamsters. Mechanistically, an intranasal omicron booster immunization bypassed deleterious immune imprinting following intramuscular ancestral strain prime, which allowed for induction of de novo lung B cell and antibody responses against the omicron strain. Cross-reactive memory T cells were also efficiently recruited into the lungs. These findings support further testing of mucosal booster vaccines against respiratory viruses, particularly as a means of simultaneously overcoming deleterious immunological imprinting and enhancing mucosal responses.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →